ASH 2022 | Results from a murine model investigating bitopertin for the treatment of EPP
Mark Fleming, MD, Boston Children’s Hospital, Boston, MA, presents the findings from a mouse model which was used to investigate the potential use of bitopertin for the treatment of erythropoietic protoporphyria (EPP). Patients with EPP are hypersensitive to the sun and experience an accumulation of protoporphyrin IX (PPIX) in the blood, which can lead to fatal liver disease. Results from this study demonstrated that bitopertin can reduce PPIX accumulation and liver damage, and this agent will soon be explored in a Phase I trial. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
DISC medicine: Current holder of stock options in a privately-held company, Honoraria.
